Metabolic medicine

Novo Nordisk Q3 2026: GLP-1 Growth, CagriSema and the Impact on Clinical Trials

Explore the six-program Boehringer–Sino oncology partnership, conditional deal economics, and implications for early-phase trial operations.

By Lampgen Clinical Research

The next chapter of metabolic medicine: oral options, combination therapies and access
Editorial illustration; devices and tablet are conceptual.

3 min read · estimated

Sources
Oral optionsCombination therapies
What Novo Nordisk’s Q3 2026 update means for evidence, execution and access

What the source reported

Novo Nordisk raised its full-year outlook on November 4, 2026, citing stronger expectations for GLP-1 product sales. Q3 sales grew 4% at constant exchange rates (CER). Adjusted operating profit increased 27%, while reported operating profit declined 9%. The adjusted comparison benefited from transformation costs recognized in Q3 2025; reported profit reflected non-cash impairments related to ziltivekimab and manufacturing-network changes. The raised outlook still puts full-year adjusted sales and operating-profit growth at −2% to +2% at CER.

Commercially, oral Wegovy generated approximately USD 0.8 billion in Q3 sales. Its rollout had reached eight markets by the announcement. These figures demonstrate commercial uptake; they do not establish that affordability or equitable access has improved.

The clinical pipeline adds another dimension. Investigational CagriSema combines the GLP-1 receptor agonist semaglutide with the amylin receptor agonist cagrilintide. Novo reported 21% average weight loss at week 68 with CagriSema 1.0/1.0 mg in REDEFINE 9. In REIMAGINE 5, the same combination dose achieved 12.4% weight loss versus 9.1% with tirzepatide 5 mg at week 60, with non-inferior HbA1c reduction.

The comparator matters: this finding does not demonstrate superiority over higher tirzepatide doses or across different populations. These are company-reported topline findings; full interpretation requires the detailed methods, analysis population, missing-data approach, safety results and treatment-discontinuation data. CagriSema remains investigational. Novo’s planned early-2027 US launch is subject to regulatory approval. The company also reported that the phase 3 AMAZE 9 trial of oral zenagamtide began in September.

What this means for trial teams

Lampgen’s interpretation is that expanding oral options and combination regimens make patient experience and study execution increasingly important. Oral treatment may suit some patients’ preferences, but convenience alone does not establish better adherence, persistence or long-term outcomes.

For trial teams, protocol-specific dosing and titration training should be paired with reliable capture of adverse events, interruptions, discontinuations and concomitant therapies. Follow-up after treatment stops helps prevent an incomplete view of effectiveness and tolerability. Recruitment plans should also address who is represented and whether visit schedules, transportation needs and other participation burdens exclude relevant populations.

For sponsors, stronger commercial uptake and additional late-stage programs are reasons to review site capacity, monitoring coverage and vendor coordination against actual study milestones.

For patients, the potential significance is greater choice in obesity and diabetes care. The practical impact will depend on regulatory decisions, tolerability, affordability, coverage and sustained access. Trial weight-loss results alone should not be treated as proof of improved cardiovascular outcomes or real-world health equity.

Lampgen specializes in oncology CRA staffing and clinical-operations support. Our perspective across development programs is consistent: reliable evidence depends on prepared sites, relevant experience, sound documentation and timely escalation.

Sources

  1. Novo Nordisk Q3 2026 financial report — November 4, 2026
  2. Novo Nordisk REIMAGINE 5 and REDEFINE 9 topline results — September 21, 2026
  3. Novo Nordisk financial results and investor materials

AVAILABLE FOR NEW PARTNERSHIPS

What does your clinical team need next?